For women with early-stage estrogen-receptor positive breast cancer, adjuvant endocrine therapy is known to decrease the likelihood of recurrence and improve survival, while omitting the therapy is associated with a higher risk of death.
Endocrine therapy, the investigators say, should therefore be offered to all patients with ER-low cancers, at least until it can be determined which subgroups are most likely to benefit., of the Mayo Clinic in Rochester, Minnesota, and her colleagues looked at 2018-2020 data from the National Cancer Database for more than 350,000 female patients with stages 1-3, ER+ breast cancer.
Forty-two percent of patients did not undergo AET as part of their treatment regimen, with various tumor factors seen associated with AET omission. At a median 3 years of follow-up, 586 patients had died. After the researchers controlled for age, comorbidities, year of diagnosis, tumor factors, and pathologic stage, the effect of omitting AET still resulted in significantly worse survival .
"We are not yet at the point of saying to patients, 'you have residual disease after chemotherapy. Let's check your tumor to see if it is the basal or luminal subtype.' But that is something that we are planning to look into. What is most important right now is that clinicians be aware of these data, and that there is a suggestion that omitting endocrine therapy may have detrimental effects on survival in this subgroup of patients.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: FCN2go - 🏆 523. / 51 Read more »
Source: people - 🏆 712. / 51 Read more »
Source: usweekly - 🏆 390. / 55 Read more »
Source: cnnbrk - 🏆 393. / 55 Read more »
Source: nbcchicago - 🏆 545. / 51 Read more »
Source: CNBC - 🏆 12. / 72 Read more »